Rebamipide Helps Defend Against Nonsteroidal Anti-Inflammatory Drugs Induced Gastroenteropathy: A Systematic Review and Meta-Analysis

@article{Zhang2013RebamipideHD,
  title={Rebamipide Helps Defend Against Nonsteroidal Anti-Inflammatory Drugs Induced Gastroenteropathy: A Systematic Review and Meta-Analysis},
  author={Shaoheng Zhang and Qing Qing and Yang Bai and Hua Mao and Wei Zhu and Qikui Chen and Yali Zhang and Ye Chen},
  journal={Digestive Diseases and Sciences},
  year={2013},
  volume={58},
  pages={1991-2000}
}
BackgroundGastrointestinal toxicity of nonsteroidal anti-inflammatory drugs (NSAIDs) has been perplexing most clinicians and users of NSAIDs. Rebamipide is increasingly advocated as a candidate option for the prevention of NSAIDs induced gastrointestinal mucosal injury.AimsTo assess the efficacy and the safety of rebamipide for the prevention and treatment of NSAID-induced gastroenteropathy.MethodsPubMed, Embase, Web of Science, Google Scholar, the Cochrane Library, Japan Science and Technology… 
Mucoprotective drugs can prevent and treat nonsteroidal anti-inflammatory drug-induced small bowel enteropathy: a systematic review and meta-analysis of randomized controlled trials
TLDR
MP treatment administered with NSAIDs can prevent and reduce small intestinal mucosal lesions.
The efficacy and safety of irsogladine maleate in nonsteroidal anti-inflammatory drug or aspirin-induced peptic ulcer and gastritis
  • K. Shim, Jin Il Kim, +11 authors Ji Won Kim
  • Medicine
    The Korean journal of internal medicine
  • 2018
TLDR
The efficacy of irsogladine maleate was found in H. pylori-negative group, suggesting its potential as a protective agent against NSAIDs or aspirin-induced peptic ulcer and gastritis.
The prevention of NSAID-induced gastric ulcers is a firmly established PPI indication
TLDR
It is concluded that PPIs should not be administered to reduce the harm of NSAIDs on gastric mucosa and should be replaced by other agents, such as rebamipide, which has been shown to protect the whole gastroenteric mucosa.
[Small bowel injuries due to nonsteroidal anti-inflammatory drugs and antiplatelet therapy. Approaches to prevention and treatment].
TLDR
Rebamipide that produces many pleiotropic effects and also has cytoprotective properties may become the drug of choice for treating patients with NSAID enteropathy.
NSAID-induced damage to the gastrointestinal tract: new opportunities for the prevention of gastro- and enteropathies
TLDR
The authors considered the effectiveness of prophylactic use of rebamipide in comparison with other strategies for the use of drugs to prevent the development of stomach ulcers, duodenal ulcers and distal small bowel ulcers.
Rebamipide and Pantoprazole Combination in NSAIDs-Gastropathy Treatment
TLDR
The research demonstrated no ulcer effects in the group of patients who were treated by rebamipide, and significantly fewer gastroduodenal erosions, in comparison to the group, where treatment contained ASA and pantoprazole.
Are Proton Pump Inhibitors Suitable Medicines to Prevent Gastrointestinal Events Due to Non-steroidal Anti-inflammatory Drugs?
Background: Proton pump inhibitors (PPIs) are often prescribed to prevent gastrointestinal (GI) events due to non-steroidal anti-inflammatory drugs (NSAIDs) in patients requiring long-term NSAIDs
Potential Strategies in the Prevention of Nonsteroidal Anti-inflammatory Drugs-Associated Adverse Effects in the Lower Gastrointestinal Tract
TLDR
An overview of the current evidence on the prevention of NSAID-related lower GI injuries is provided and selective COX-2 inhibitors, misoprostol, intestinal microbiota modulation, and some mucoprotective agents have been reported to show protective effects on NSAIDS.
[Rebamipide: New opportunities of gastroenteroprotection].
This review paper deals with the prevention and therapy of nonsteroidal anti-inflammatory drug (NSAID)-induced gastrointestinal mucosal injuries in patients with diseases of the cardiovascular and
[Pharmacological and clinical feature of rebamipide: new therapeutic targets].
TLDR
The aim of this review is to present current information about the pharmacological and clinical feature of rebamipide and to study its therapeutic potential.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 58 REFERENCES
Prevention of NSAID-induced gastroduodenal ulcers.
TLDR
Misoprostol, PPIs, and double dose H2RAs are effective at preventing chronic NSAID related endoscopic gastric and duodenal ulcers and was the only prophylactic agent documented to reduce ulcer complications.
A Comparison of Efficacy between Rebamipide and Omeprazole in the Treatment of NSAIDs Gastropathy
TLDR
Omeprazole is more effective than rebamipide in improvement of NSAIDs induced gastropathy and is as safe as rebamIPide in the treatment ofNSAIDs induced Gastropathy.
Comparison of Prevention of NSAID-Induced Gastrointestinal Complications by Rebamipide and Misoprostol: A Randomized, Multicenter, Controlled Trial—STORM STUDY
TLDR
Rebamipide prevented NSAID-induced peptic ulcer as effectively as misoprostol in patients on long-term NSAID therapy and may be a useful therapeutic option for the prevention of NSAIDs-induced gastrointestinal ulcer.
Assessing the efficacy of famotidine and rebamipide in the treatment of gastric mucosal lesions in patients receiving long-term NSAID therapy (FORCE—famotidine or rebamipide in comparison by endoscopy)
TLDR
Famotidine was superior to rebamipide in treating NSAID-associated mucosal lesions in patients taking NSAIDs for either gastric hemorrhage or erosion.
Nonsteroidal anti-inflammatory drug gastropathy.
TLDR
Risk is dose dependent and is lower with ibuprofen at low doses than with other NSAIDs, and it is unlikely that Helicobacter pylori increases the risk, and under some circumstances it may be protective.
Prevention of Indomethacin-Induced Gastric Mucosal Injury in Helicobacter pylori-Negative Healthy Volunteers: A Comparison Study Rebamipide vs Famotidine
TLDR
Rebamipide or famotidine are recommended for the prevention of acute gastric injury induced by NSAID in patients without a particular risk factor, as indicated by the results of a randomized, two way crossover study.
Epidemiology of nonsteroidal anti-inflammatory drug-associated gastrointestinal injury.
  • M. Griffin
  • Medicine
    The American journal of medicine
  • 1998
Rebamipide has the potential to reduce the intensity of NSAID-induced small intestinal injury: a double-blind, randomized, controlled trial evaluated by capsule endoscopy
TLDR
Rebamipide co-therapy had the potential to reduce the intensity of small intestinal injury induced by 2-week administration of diclofenac.
Efficacy of rebamipide for diclofenac-induced small-intestinal mucosal injuries in healthy subjects: a prospective, randomized, double-blinded, placebo-controlled, cross-over study
TLDR
Rebamipide had significantly higher efficacy than placebo in preventing NSAID-induced small-intestinal mucosal injury.
NSAID gastropathy and enteropathy: distinct pathogenesis likely necessitates distinct prevention strategies
  • J. Wallace
  • Medicine
    British journal of pharmacology
  • 2012
The mechanisms underlying the ability of nonsteroidal anti‐inflammatory drugs (NSAIDs) to cause ulceration in the stomach and proximal duodenum are well understood, and this injury can largely be
...
1
2
3
4
5
...